News

As part of the transaction, Gaymar has also acquired a new license agreement that gives the company exclusive worldwide rights to new gel technologies, offering promise for potential

The acquired product line includes Enlon (edrophonium chloride injection, USP) 10mg/ml, 15ml vial, Enlon-Plus (edrophonium chloride, USP and atropine sulfate, USP) injection 5ml ampule and Enlon-Plus (edrophonium chloride,

The agreement covers the late-stage development and commercialization of ATI-7505, a prokinetic agent in Phase II clinical trials for chronic constipation and functional dyspepsia. Under the terms of

This acquisition is expected to accelerate USHIFU’s ability to expand the Focus Surgery’s high-intensity focused ultrasound (HIFU) technology platform, as well as gain access to new markets, such

Under the terms of the sales and marketing agreement, Patheon will promote BSP’s cytotoxic manufacturing capacity and development services. Aldo Braca, president of Patheon Europe will be president

The Xience V drug coated stent is used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a

A consortium led by McKesson, which includes Oracle and IBM, will supply National Health Service (NHS) with the system, called electronic staff record (ESR), a $480 million contract

The initial contract was awarded through the transformational medical technologies initiative of the US Department of Defense’s Defense Threat Reduction Agency (DTRA). Under the terms of the contact,

Celera has become an independent publicly traded company that holds the businesses, assets and liabilities previously attributed to the Celera Group. With the separation of Celera, Applera will